Research map: Combination Treatment Strategies With Peptide Receptor Radionuclide Therapy

Back to the article

Papers in this map

  1. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group · Anja Rinke · 2009 · 2528 citations · Cited by this paper
  2. Radiation-induced Continuous False-positive 18F-MFBG Uptake in the Perirenal Space of a Pediatric Neuroblastoma Patient · 2026 · Related
  3. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors · Martyn Evan Caplin · 2014 · 1958 citations · Cited by this paper
  4. Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma · 2026 · Related
  5. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up · Marianne Ellen Pavel · 2020 · 1196 citations · Cited by this paper
  6. Renal Ewing Sarcoma Mimicking Neuroblastoma · 2026 · Related
  7. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms · Guido Rindi · 2022 · 1032 citations · Cited by this paper
  8. 18F-MFBG Uptake From Multiple Focal “Hot Spots” to Superscan in a Pediatric Patient With High-risk Neuroblastoma · 2026 · Related
  9. First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas · Jonathan Strosberg · 2010 · 772 citations · Cited by this paper
  10. Rechallenge With 177Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer · 2026 · Related
  11. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial · Jonathan R Strosberg · 2021 · 583 citations · Cited by this paper
  12. Intrapulmonary Myelolipoma Depicted by 18F-FDG PET/CT · 2026 · Related
  13. Application of Radiosensitizers in Cancer Radiotherapy · Liuyun Gong · 2021 · 492 citations · Cited by this paper
  14. FAPI-negative Papillary Renal Cell Carcinoma With Markedly FAPI-avid Sacral Insufficiency Fracture · 2026 · Related
  15. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy · Ute Hennrich · 2019 · 433 citations · Cited by this paper
  16. Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Demonstration of Masticatory Myositis Associated With Behçet’s Disease · 2026 · Related
  17. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study · Simron Singh · 2024 · 374 citations · Cited by this paper
  18. Rapid Lymphatic Clearance After Subcutaneous Extravasation of 177Lu-PSMA-I&T Radioligand Therapy · 2026 · Related
  19. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues · Rodney John Hicks · 2017 · 343 citations · Cited by this paper
  20. Complete Pachydermoperiostosis With Acromegaloid Phenotype: Characteristic 99mTc-Methylene Diphosphonate (MDP) Skeletal Scintigraphy in a Rare Clinical Mimic of Acromegaly · 2026 · Related
  21. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies · Lowell Brian Anthony · 2002 · 280 citations · Cited by this paper
  22. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? · Jolanta Kunikowska · 2011 · 240 citations · Cited by this paper
  23. Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE · Ezgi Ilan · 2015 · 229 citations · Cited by this paper
  24. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours · Phillip G. Claringbold · 2010 · 212 citations · Cited by this paper
  25. Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers · Linda Villard · 2012 · 190 citations · Cited by this paper
  26. European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for gastroduodenal neuroendocrine tumours ( NETs) G1–G3 · Francesco Panzuto · 2023 · 182 citations · Cited by this paper
  27. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms · Richard Paul Baum · 2018 · 142 citations · Cited by this paper
  28. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours · Martijn van Essen · 2008 · 133 citations · Cited by this paper
  29. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate · Esther I. van Vliet · 2015 · 126 citations · Cited by this paper
  30. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy · Rocio García‐Carbonero · 2017 · 125 citations · Cited by this paper
  31. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy · Richard Paul Baum · 2021 · 121 citations · Cited by this paper
  32. Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours · Raghava K Kashyap · 2014 · 114 citations · Cited by this paper
  33. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy · Phillip G. Claringbold · 2015 · 111 citations · Cited by this paper
  34. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms · Stefano Partelli · 2017 · 104 citations · Cited by this paper
  35. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung · Chul Kim · 2020 · 94 citations · Cited by this paper
  36. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT) · Grace Kong · 2014 · 93 citations · Cited by this paper
  37. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225 Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study · Sanjana Ballal · 2022 · 90 citations · Cited by this paper
  38. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors · Sanjana Ballal · 2017 · 87 citations · Cited by this paper
  39. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study · Arthur J. A. T. Braat · 2020 · 80 citations · Cited by this paper

Source: OpenAlex (CC0)